Results 321 to 330 of about 777,795 (407)

Glial Fibrillary Acidic Protein Astrocytopathy Based on a Two‐Center Chinese Cohort Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Glial fibrillary acidic protein astrocytopathy (GFAP‐A) is a recently defined nosological form belonging to the class of autoimmune inflammatory disorders affecting the central nervous system (CNS). Here, we report the clinical and MRI characteristics, treatment, and prognosis of a GFAP‐A cohort from two centers in China.
Ti Wu, Hao Zhang, Chao Gao, Qiuhua Yu, Moli Fan, Lin‐Jie Zhang, Haipeng Zhang, Hengri Cong, Yuzhen Wei, Chotima Böttcher, Alexej Verkhratsky, Friedemann Paul, Fu‐Dong Shi, Tian Song   +13 more
wiley   +1 more source

The Comparative Effectiveness and Tolerability of Sphingosine‐1‐Phosphate Receptor Modulators in Patients With Multiple Sclerosis: A Network Meta‐Analysis of Randomized Controlled Trials

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Sphingosine‐1‐phosphate receptor modulators (S1PRM) are used to treat relapsing multiple sclerosis (MS). Each drug has a different S1PR‐subtype selectivity. They target the G‐protein coupled S1P receptors and exert significant immunomodulatory effects, such as preventing the formation of new CNS lesions and the reactivation of pre ...
Faizan Shahzad, Taimoon Rasheed, Momina Riaz Siddiqui, Hamza Hamid, Marwah Bintay Khalid, Haroon Shabbir, Besher Shami, Abdullah, Syed Ijlal Ahmed   +8 more
wiley   +1 more source

GPCR-BSD: a database of binding sites of human G-protein coupled receptors under diverse states. [PDF]

BMC Bioinformatics
Liu F, Zhou H, Li X, Zhou L, Yu C, Zhang H, Bu D, Liang X.   +7 more
europepmc   +1 more source

Discovery and Treatment of Action Potential‐Independent Myotonia in Hyperkalemic Periodic Paralysis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Hyperkalemic periodic paralysis (hyperKPP) is characterized by attacks of transient weakness. A subset of hyperKPP patients suffers from transient involuntary contraction of muscle (myotonia). The goal of this study was to determine mechanisms causing myotonia in hyperKPP.
Chris Dupont, Adam Deardorff, Murad Nawaz, Andrew A. Voss, Mark M. Rich   +4 more
wiley   +1 more source

De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors

Muratspahić E, Feldman D, Kim DE, Qu X, Bratovianu A, Rivera-Sánchez P, Dimitri F, Cao J, Cary BP, Belousoff MJ, Keov P, Chen Q, Ren Y, Fine J, Sappington I, Schlichthaerle T, Zhang JZ, Pillai A, Mihaljević L, Bauer M, Torres SV, Motmaen A, Lee GR, Tran L, Wang X, Goreshnik I, Vafeados DK, Svendsen JE, Hosseinzadeh P, Lindegaard N, Brandt M, Waltenspühl Y, Deibler K, Oostdyk L, Cao W, Anantharaman L, Stewart L, Halloran L, Spangler JB, Sexton PM, Roth BL, Krumm BE, Wootten D, Tate CG, Norn C, Baker D.   +45 more
europepmc   +1 more source

Information Transmission in G Protein-Coupled Receptors. [PDF]

Int J Mol Sci
Jones RD.
europepmc   +1 more source

Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia, Stephane Rodriguez, Emilie Dugast, Christine Lebrun‐Frenay, Eric Thouvenot, Jérôme de Sèze, Emmanuelle Le Page, Sandra Vukusic, Inès Doghri, Eric Berger, Olivier Casez, Pierre Labauge, Aurélie Ruet, Catarina Raposo, Fabienne Le Frère, Arnaud B. Nicot, Sandrine Wiertlewski, Pierre‐Antoine Gourraud, Laure Michel, Laureline Berthelot, David‐Axel Laplaud   +20 more
wiley   +1 more source

G protein-coupled receptors: from radioligand binding to cellular signaling. [PDF]

J Clin Invest
Rockman HA, Lefkowitz RJ.
europepmc   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski, Aurélie Ledreux, John E. Violette, Whitney Paustian, Stefan Sillau, John A. Thompson, Robert T. Neumann, David Ornelas, Andrew A. Monte, Layne Dylla, Adit A. Ginde, Andra M. Farcas, Christina M. Coughlan, William J. Jones, James C. Grotta, Michael W. Graner   +15 more
wiley   +1 more source

G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery. [PDF]

Signal Transduct Target Ther
Zhang M, Chen T, Lu X, Lan X, Chen Z, Lu S.   +5 more
europepmc   +1 more source